Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China

Leuk Lymphoma. 2017 Jul;58(7):1624-1629. doi: 10.1080/10428194.2016.1257793. Epub 2016 Nov 20.

Abstract

We carried out a single-center retrospective study to assess the predictive value of body mass index (BMI) in the outcome of Chinese patients with diffuse large B-cell lymphoma (DLBCL). 143 eligible patients were enrolled between January 2008 and May 2015. These patients were stratified into two groups, 74 patients in low BMI group (BMI <23.0 kg/m2) and 69 patients in high BMI group (BMI ≥23.0 kg/m2). We compared the baseline characteristics, primary response, and survival outcome in two groups. Well-known influence factors were similar between the two groups, while gender was not (p = .023) but did not act as a risk factor. No association between BMI and primary response was observed. Patients with high BMI were inclined to have better overall survival (OS) (p = .018), but we didn't find an association in progression-free survival (PFS) (p = .067). We also found a sex-dependent effect of BMI on OS, with high BMI increased OS in female patients (p = .027) but showed no correlation in male patients (p = .310).

Keywords: Body mass index; clinical outcome; diffuse large B-cell lymphoma.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers
  • Body Mass Index*
  • China / epidemiology
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / epidemiology*
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Male
  • Population Surveillance
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Biomarkers